Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

The Association Between Eating-Compensatory Behaviors and Affective Temperament in a Brazilian Population.

Chapuis-de-Andrade S, Moret-Tatay C, Costa DB, Abreu da Silva F, Irigaray TQ, Lara DR.

Front Psychol. 2019 Aug 23;10:1924. doi: 10.3389/fpsyg.2019.01924. eCollection 2019.

2.

miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.

Zhang WC, Wells JM, Chow KH, Huang H, Yuan M, Saxena T, Melnick MA, Politi K, Asara JM, Costa DB, Bult CJ, Slack FJ.

Nat Metab. 2019 Apr;1(4):460-474. doi: 10.1038/s42255-019-0052-9. Epub 2019 Apr 8.

3.

TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.

Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi SS.

Mol Cancer Res. 2019 Aug 29. doi: 10.1158/1541-7786.MCR-19-0419. [Epub ahead of print]

PMID:
31467113
4.

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.

Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB.

J Thorac Oncol. 2019 Aug 1. pii: S1556-0864(19)30599-4. doi: 10.1016/j.jtho.2019.07.016. [Epub ahead of print]

PMID:
31377341
5.

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS.

Lung Cancer. 2019 Jul;133:96-102. doi: 10.1016/j.lungcan.2019.05.011. Epub 2019 May 11.

PMID:
31200835
6.

From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.

Rangachari D, Costa DB.

J Clin Oncol. 2019 Oct 1;37(28):2511-2513. doi: 10.1200/JCO.19.01207. Epub 2019 Jun 2. No abstract available.

PMID:
31154918
7.

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.

Varkaris A, Sehgal K, Rangachari D, Costa DB.

J Thorac Oncol. 2019 Feb;14(2):e34-e36. doi: 10.1016/j.jtho.2018.10.157. No abstract available.

PMID:
30683297
8.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV.

J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16. Erratum in: J Clin Oncol. 2019 Mar 1;37(7):612.

9.

Authors' Response.

Cheng MP, Marty FM, Costa DB, Awad MM.

J Thorac Oncol. 2018 Nov;13(11):e237. doi: 10.1016/j.jtho.2018.09.015. No abstract available.

PMID:
30368420
10.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.

Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV.

Ann Oncol. 2018 Oct 1;29(10):2092-2097. doi: 10.1093/annonc/mdy336.

PMID:
30351341
11.

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors.

Sehgal K, Patell R, Rangachari D, Costa DB.

Transl Cancer Res. 2018 Aug;7(Suppl 7):S779-S786. doi: 10.21037/tcr.2018.08.11. No abstract available.

12.

TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.

Costa DB.

Ann Oncol. 2018 Oct 1;29(10):2028-2030. doi: 10.1093/annonc/mdy339. No abstract available.

13.

Lung Cancer with a High Tumor Mutational Burden.

VanderLaan PA, Rangachari D, Costa DB.

N Engl J Med. 2018 Sep 13;379(11):1093. doi: 10.1056/NEJMc1808566. No abstract available.

PMID:
30211492
14.

Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.

Shea M, Rangachari D, Hallowell RW, Hollie NI, Costa DB, VanderLaan PA.

Cancer Treat Res Commun. 2018;15:17-20. doi: 10.1016/j.ctarc.2018.02.004. Epub 2018 Feb 21.

PMID:
30207283
15.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB.

Clin Cancer Res. 2018 Dec 15;24(24):6548-6555. doi: 10.1158/1078-0432.CCR-18-1541. Epub 2018 Aug 28.

PMID:
30154228
16.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA.

JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969.

17.

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA.

Clin Cancer Res. 2018 Dec 1;24(23):5963-5976. doi: 10.1158/1078-0432.CCR-18-0876. Epub 2018 Aug 2.

PMID:
30072474
18.

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.

Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB.

J Thorac Oncol. 2019 Jan;14(1):e1-e3. doi: 10.1016/j.jtho.2018.06.020. Epub 2018 Jul 5. No abstract available.

PMID:
29981924
19.

Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.

VanderLaan PA, Chen Y, DiStasio M, Rangachari D, Costa DB, Heher YK.

Clin Lung Cancer. 2018 Sep;19(5):e589-e590. doi: 10.1016/j.cllc.2018.04.005. Epub 2018 May 4. No abstract available.

PMID:
29798809
20.

PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?

Torous VF, Rangachari D, Gallant BP, Shea M, Costa DB, VanderLaan PA.

J Am Soc Cytopathol. 2018 May-Jun;7(3):133-141. doi: 10.1016/j.jasc.2018.02.003. Epub 2018 Feb 16.

21.

Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting.

Rangachari D, VanderLaan PA, Costa DB.

J Thorac Oncol. 2018 May;13(5):e81-e83. doi: 10.1016/j.jtho.2018.01.023. No abstract available.

22.

Personality factors and cognitive functioning in elderly with Parkinson's disease.

Chardosim NMO, Oliveira CR, Lima MP, Farina M, Gonzatti V, Costa DB, Pereira AS, Paloski LH, Irigaray TQ, Argimon IIL.

Dement Neuropsychol. 2018 Jan-Mar;12(1):45-53. doi: 10.1590/1980-57642018dn12-010007.

23.

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.

Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM.

J Thorac Oncol. 2018 Jul;13(7):1037-1042. doi: 10.1016/j.jtho.2018.03.031. Epub 2018 Apr 6.

24.

Tumor biomarker testing in non-small-cell lung cancer: A decade of change.

VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS, Costa DB.

Lung Cancer. 2018 Feb;116:90-95. doi: 10.1016/j.lungcan.2018.01.002. Epub 2018 Jan 4.

25.

Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT.

Heidinger BH, Anderson KR, Nemec U, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA.

J Thorac Dis. 2017 Dec;9(12):E1148-E1150. doi: 10.21037/jtd.2017.11.25. No abstract available.

26.

Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.

Le X, Rangachari D, Costa DB.

J Thorac Dis. 2017 Sep;9(9):2812-2818. doi: 10.21037/jtd.2017.08.79. No abstract available.

27.

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

Carney BJ, Rangachari D, VanderLaan PA, Gowen K, Schrock AB, Ali SM, Costa DB.

Lung Cancer. 2017 Dec;114:108-110. doi: 10.1016/j.lungcan.2017.08.018. Epub 2017 Aug 24. No abstract available.

PMID:
28870636
28.

Animal Hoarding Disorder: A new psychopathology?

Ferreira EA, Paloski LH, Costa DB, Fiametti VS, De Oliveira CR, de Lima Argimon II, Gonzatti V, Irigaray TQ.

Psychiatry Res. 2017 Dec;258:221-225. doi: 10.1016/j.psychres.2017.08.030. Epub 2017 Aug 18.

PMID:
28843626
29.

"Rounding" the Size of Pulmonary Nodules: Impact of Rounding Methods on Nodule Management, as Defined by the 2017 Fleischner Society Guidelines.

Heidinger BH, Nemec U, Anderson KR, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA.

Acad Radiol. 2017 Nov;24(11):1422-1427. doi: 10.1016/j.acra.2017.05.013. Epub 2017 Jun 27.

PMID:
28666724
30.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB.

J Thorac Oncol. 2017 Nov;12(11):e175-e177. doi: 10.1016/j.jtho.2017.06.002. Epub 2017 Jun 10. No abstract available.

31.

Ascending role of next-generation ALK inhibitors.

Costa DB.

Lancet Oncol. 2017 Jul;18(7):837-839. doi: 10.1016/S1470-2045(17)30338-8. Epub 2017 Jun 9. No abstract available.

PMID:
28602777
32.

Scientific Advances in Thoracic Oncology 2016.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.

J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1. Review.

33.

Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size.

Heidinger BH, Anderson KR, Nemec U, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA.

J Thorac Oncol. 2017 Aug;12(8):1288-1298. doi: 10.1016/j.jtho.2017.05.017. Epub 2017 May 30.

34.

Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.

DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA.

Clin Lung Cancer. 2017 Sep;18(5):e349-e356. doi: 10.1016/j.cllc.2017.03.001. Epub 2017 Mar 14.

PMID:
28377205
35.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.

Peters MLB, Costa DB, Rangachari D.

J Thorac Oncol. 2017 Apr;12(4):e35-e36. doi: 10.1016/j.jtho.2016.12.018. No abstract available.

36.

[Use of medicines before and during pregnancy: prevalence and associated factors].

Costa DB, Coelho HL, Santos DB.

Cad Saude Publica. 2017 Mar 9;33(2):e00126215. doi: 10.1590/0102-311X00126215. Portuguese.

37.

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB.

Lung Cancer. 2017 Apr;106:17-21. doi: 10.1016/j.lungcan.2017.01.011. Epub 2017 Jan 25.

38.

Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules ≤30 mm on CT: Radiology-Pathology Correlation.

Heidinger BH, Anderson KR, Moriarty EM, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA.

Acad Radiol. 2017 Jul;24(7):851-859. doi: 10.1016/j.acra.2017.01.009. Epub 2017 Feb 28.

PMID:
28256438
39.

Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease.

Rangachari D, Costa DB.

Transl Cancer Res. 2017 Feb;6(Suppl 1):S151-S157. doi: 10.21037/tcr.2017.02.28. No abstract available.

40.

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

Rangachari D, Drake L, Huberman MS, McDonald DC, VanderLaan PA, Folch E, Costa DB.

Cancer Treat Commun. 2016;9:41-43. doi: 10.1016/j.ctarc.2016.07.001. Epub 2016 Jul 5.

41.

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.

Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB.

J Thorac Oncol. 2017 May;12(5):878-883. doi: 10.1016/j.jtho.2016.12.026. Epub 2017 Jan 16.

42.

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB.

Clin Lung Cancer. 2016 Nov;17(6):483-492. doi: 10.1016/j.cllc.2016.05.016. Epub 2016 Jun 8. Review.

PMID:
27381270
43.

Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?

Costa DB.

Cell Cycle. 2017 Jan 2;16(1):19-20. doi: 10.1080/15384101.2016.1247568. Epub 2016 Oct 20. No abstract available.

44.

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.

Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB.

Lung Cancer. 2016 Sep;99:17-22. doi: 10.1016/j.lungcan.2016.06.006. Epub 2016 Jun 14.

46.

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.

Redig AJ, Costa DB, Taibi M, Boucher D, Johnson BE, Jänne PA, Jackman DM.

JAMA Oncol. 2016 Sep 1;2(9):1240-2. doi: 10.1001/jamaoncol.2016.1304. No abstract available.

PMID:
27387964
47.

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA.

Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. Epub 2016 Jun 8.

48.

Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence.

Gao X, VanderLaan PA, Bailey AS, Costa DB.

Clin Lung Cancer. 2016 Sep;17(5):e169-e172. doi: 10.1016/j.cllc.2016.03.006. Epub 2016 Mar 30. No abstract available.

PMID:
27103378
49.

Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline.

Chen CA, Costa DB, Wu PA.

JAAD Case Rep. 2015 Jul 30;1(5):289-91. doi: 10.1016/j.jdcr.2015.06.013. eCollection 2015 Sep. No abstract available.

50.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS.

J Clin Oncol. 2016 Aug 20;34(24):2858-65. doi: 10.1200/JCO.2015.63.5888. Epub 2016 Mar 28.

PMID:
27022118

Supplemental Content

Loading ...
Support Center